acalabrutinib + rituximab + ifosfamide + carboplatin + etoposide

This combination therapy consists of acalabrutinib, a second-generation Bruton tyrosine kinase (BTK) inhibitor, administered alongside the R-ICE chemoimmunotherapy regimen (rituximab, ifosfamide, carboplatin, and etoposide). Acalabrutinib works by forming an irreversible covalent bond with BTK at the Cys481 residue, inhibiting the B-cell receptor signaling pathway which is critical for the survival and proliferation of malignant B-cells. Rituximab is a monoclonal antibody that targets the CD20 antigen on B-cells, inducing cell death through various immune-mediated mechanisms. Ifosfamide, carboplatin, and etoposide are cytotoxic agents that provide synergistic antineoplastic effects through DNA alkylation and inhibition of topoisomerase II. This specific combination is being investigated by the University of Miami in a Phase 2 clinical trial for patients with relapsed or refractory aggressive B-cell lymphomas, specifically non-germinal center diffuse large B-cell lymphoma (DLBCL), transformed chronic lymphocytic leukemia (CLL), transformed small lymphocytic lymphoma (SLL), and transformed marginal zone lymphoma (MZL).

Other names

acalabrutinib + R-ICEacalabrutinib plus R-ICE